Genmab — Share Issue/Capital Change 2013

Jan 31, 2013

Company Announcement

Copenhagen, Denmark; January 31,
2013 – Genmab A/S (OMX: GEN) announced today that at a board
meeting the board decided to issue 4,250
warrants to employees of the company as well as the company’s
subsidiaries.

The
exercise price for each warrant is DKK 98.00. Each warrant entitles the owner
to subscribe one share of nominally DKK 1. On the basis of an exercise price of
DKK 98.00 and by application of the Black-Scholes formula, the average value of
each warrant can be calculated as DKK 41.73 based on an interest rate of
0.2870% and the historical volatility of Genmab A/S shares calculated at
53.56%.

The warrants vest in blocks of 25% one, two, three and
four years after the grant date, and all warrants expire at the seventh
anniversary of the grant date. The new warrants were granted pursuant to the
warrant plan adopted by the board on April 25, 2012. Information concerning
Genmab’s warrant schemes can be found on www.genmab.com under
Investors > Stock information >
Warrants.

About Genmab A/S
Genmab is a publicly traded, international
biotechnology company specializing in the creation and development of
differentiated human antibody therapeutics for the treatment of cancer.
Founded in 1999, the company’s first marketed antibody, ofatumumab (Arzerra®),
was approved to treat chronic lymphocytic leukemia in patients who are
refractory to fludarabine and alemtuzumab after less than eight years in
development. Genmab’s validated and next generation antibody technologies are
expected to provide a steady stream of future product candidates. Partnering
of innovative product candidates and technologies is a key focus of Genmab’s
strategy and the company has alliances with top tier pharmaceutical and
biotechnology companies. For more information visit www.genmab.com.

Contact:
Rachel
Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E:
r.gravesen@genmab.com

This Company Announcement contains
forward looking statements. The words “believe”, “expect”, “anticipate”,
“intend” and “plan” and similar expressions identify forward looking
statements. Actual results or performance may differ materially from any future
results or performance expressed or implied by such statements. The important
factors that could cause our actual results or performance to differ materially
include, among others, risks associated with pre-clinical and clinical
development of products, uncertainties related to the outcome and conduct of
clinical trials including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our products, our
inability to manage growth, the competitive environment in relation to our
business area and markets, our inability to attract and retain suitably
qualified personnel, the unenforceability or lack of protection of our patents
and proprietary rights, our relationships with affiliated entities, changes and
developments in technology which may render our products obsolete, and other
factors. For a further discussion of these risks, please refer to the risk
management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by
law.

Genmab A/S and its subsidiaries own the following
trademarks: Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; DuoBody®, HexaBody(TM) and UniBody®. Arzerra® is a trademark of GlaxoSmithKline.

Company Announcement no. 02
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark